Aerie Pharmaceuticals (NSDQ:AERI) said today that it inked a collaborative R&D and licensing agreement with DSM to develop an implantable drug-delivery system for patients with glaucoma and other retinal diseases.
DSM has reportedly developed an injectable drug-delivery fiber using polyesteramide polymers that has proven successful in preclinical work with Aerie’s compounds.
Get the full story at our sister site, Drug Delivery Business News.
The post Aerie inks deal for implantable drug-delivery system appeared first on MassDevice.
from MassDevice http://ift.tt/2vaPJbO
Cap comentari:
Publica un comentari a l'entrada